Sustained Type Ⅰ interferon signaling as a mechanism of resistance to PD-1 blockade
29
We would like to particularly thanks the animal facility,the Flowcytometry and Pathology Platforms of Gustave Roussy,especially Dr.Patrick Gonin,Laure Touchard,Philippe Rameau,and Olivia Bawa.We thank the Professors Antoine Durrbach and Gilles Uzé for providing Abatacept and lfnar1-/-mice,respectiv;ANR,Ligue contre le cancer and Swiss Bridge Foundation,ISREC Foundation,LABEX Oncolmmunology,la direction générale de l”offre de soins;Université Paris-Sud,PIA2 TORINO-LUMIERE,Chancelerie des universités de Paris;Fondation pour la Recherche Médicale;a donation by Elior;European Research Area Network on Cardiovascular Diseases;Gustave Roussy Odyssea,the European Union Horizon 2020 Project Oncobiome;Fondation Carrefour;Inserm;Institut Universitaire de France;LeDucq Foundation;the LabEx Immuno-Oncology;the RHU Torino Lumière;the Seerave Foundation;the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination;the SIRIC Cancer Research and Personalized Medicine CARPEM.N.J.received a fellowship from Fondation ARC pour la recherche sur le cancer and is supported by grant 1163990 awarded through the 2018 Priority-driven Collaborative Cancer Research Scheme and co-funded by Cancer Australia and Cure Cancer.;from the Dr.Miriam and Sheldon G.Adelson Medical Research Foundation,and the AIM at Melanoma Foundation.This work was supported by grants from Italian Miinistry of Health through ”Ricerca Corrente”.G.M.is funded by Istitutional ”Ricerca Corrente”.M.J.S.was supported by a NHMRC of Australia Senior Pr1078671;Program Grant 1132519.V.B.and S.U.are supported by the Italian Association for Cancer Research AIRC 12182,21509 and 18603.S.F.N.was supported by an Australia NHMRC CJ Martin Fellowship1111469
2019-12-11(万方平台首次上网日期,不代表论文的发表时间)
共16页
846-861